» Articles » PMID: 30702258

Renal Cell Carcinoma: Diagnosis and Management

Overview
Specialty Public Health
Date 2019 Feb 1
PMID 30702258
Citations 153
Authors
Affiliations
Soon will be listed here.
Abstract

Kidney cancer is one of the 10 most common cancers in the United States with 90% being attributed to renal cell carcinoma. Men, especially black men, are more likely to be affected than women. Renal masses, either cystic or solid, are best detected with contrast-enhanced, triple-phase computed tomography. Renal tumors are often detected incidentally during a computed tomography scan of the abdomen or chest that was ordered for unrelated symptoms. Hematuria serves as a warning sign that necessitates further evaluation and imaging leading to a diagnosis and treatment plan. Treatment options include active surveillance, ablation, nephron-sparing tumor excision, nephrectomy, and systemic treatment. Predictors of a poor prognosis include poor functional status and metastasis. In recent years new therapies have improved the prognosis for patients with metastatic disease. The family physician should be aware of risk factors (e.g., hypertension, tobacco use, exposure to trichloroethylene, familial syndromes) and lifestyle and dietary modifications that may reduce risk.

Citing Articles

Efficacy and safety of PD-1/PD-L1 inhibitors alone or in combination in the treatment of metastatic or advanced renal cell carcinoma: a network meta-analysis.

Zhang D, Shen C, Zhang W, Chen H, Zhao J Front Immunol. 2025; 16:1524497.

PMID: 40070839 PMC: 11893867. DOI: 10.3389/fimmu.2025.1524497.


Lathyrol affects the expression of AR and PSA and inhibits the malignant behavior of RCC cells.

Song S, Tai L, Zhou L, Jiang J, Zhao J Open Med (Wars). 2025; 20(1):20241136.

PMID: 39927164 PMC: 11806241. DOI: 10.1515/med-2024-1136.


Molecular mechanisms of renal cell carcinoma metastasis and potential targets for therapy.

Li X, Xiong W, Xiong Z, Zhang X Front Cell Dev Biol. 2025; 13:1521151.

PMID: 39901876 PMC: 11788337. DOI: 10.3389/fcell.2025.1521151.


Plasma proteome fingerprint in kidney diseases.

Nikolsky K, Kopylov A, Nakhod V, Potoldykova N, Enikeev D, Butkova T Front Mol Biosci. 2025; 11:1494779.

PMID: 39896931 PMC: 11782039. DOI: 10.3389/fmolb.2024.1494779.


Dual-Stage AI Model for Enhanced CT Imaging: Precision Segmentation of Kidney and Tumors.

Karunanayake N, Lu L, Yang H, Geng P, Akin O, Furberg H Tomography. 2025; 11(1).

PMID: 39852683 PMC: 11769543. DOI: 10.3390/tomography11010003.